Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion

Fineline Cube Mar 12, 2026
Deals Drug

Huadong Medicine’s HDM2024 Wins FDA Phase I Approval – First-in-Class EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors

Fineline Cube Mar 12, 2026
Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Fineline Cube Mar 11, 2026
Company Deals Drug

AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences

Fineline Cube Mar 11, 2026
Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer

Fineline Cube Mar 12, 2026
Company Drug

Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers

Fineline Cube Mar 12, 2026
Company Deals

Boao Lecheng Partners with China National Center for Neurological Diseases to Establish Translational Center

Fineline Cube Jun 23, 2025

The Boao Lecheng International Medical Tourism Pilot Zone Administration announced last week a strategic cooperation...

Company Drug

Sichuan Huiyu’s CDCP1-Targeted ADC HY0001a Gets NMPA Clinical Trial Approval

Fineline Cube Jun 23, 2025

China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) announced that it has received clinical trial...

Company Drug

Changshan Biochemical Receives NMPA Clearance for Albenatide in Weight Loss Trials

Fineline Cube Jun 23, 2025

China’s Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) announced that it has received...

Company Drug

ImmuneOnco Receives NMPA Approval for IMC-003/IMM72 in Pulmonary Arterial Hypertension Trial

Fineline Cube Jun 23, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced that it has received clinical trial...

Company Deals

United Imaging Intelligence Closes RMB 1B Series A Round to Boost AI in Healthcare

Fineline Cube Jun 23, 2025

United Imaging Intelligence, the AI-focused subsidiary of Shanghai United Imaging Healthcare Co., Ltd., reportedly secured...

Company Medical Device

MGI Tech’s DNBSEQ-T1+ Gains CE IVDR Certification for EU Market Entry

Fineline Cube Jun 23, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) announced that its latest mid-throughput...

Company Deals

Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million

Fineline Cube Jun 23, 2025

China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake...

Company Drug

Simcere Pharma’s Quviviq Receives NMPA Approval for Insomnia Treatment

Fineline Cube Jun 23, 2025

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) revealed that its marketing approval filing for Quviviq...

Company Drug

Sanofi and Regeneron Win FDA Approval for Dupixent in Bullous Pemphigoid Treatment

Fineline Cube Jun 23, 2025

France major Sanofi (NASDAQ: SNY) and US-based biopharma Regeneron (NASDAQ: REGN) announced that Dupixent (dupilumab)...

Company Drug

Zai Lab’s Partner argenx Secures EU Approval for Vygart in CIDP Treatment

Fineline Cube Jun 23, 2025

China-based Zai Lab Limited’s (NASDAQ: ZLAB, HKG: 9688) Dutch partner argenx SE (NASDAQ: ARGX) announced...

Company Deals

Harbour BioMed and Otsuka Pharma Collaborate Globally on BCMAxCD3 Bispecific T-cell Engager

Fineline Cube Jun 23, 2025

China-based Harbour BioMed (HKG: 2142) has entered into a global strategic collaboration with Japan-headquartered Otsuka...

Company Drug

CanSino Biologics’ PCV13i Vaccine Gains NMPA Approval

Fineline Cube Jun 23, 2025

China-based CanSino Biologics Inc., (HKG: 6185) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Zhongsheng Pharma’s RAY1225 Enters Phase III Trial for Obesity/Overweight Treatment

Fineline Cube Jun 20, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the initiation of the multi-center, randomized,...

Company Drug

Dizal’s Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC

Fineline Cube Jun 20, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its...

Company Drug

Shanghai Pharmaceuticals Receives Thai FDA Approval for Pregabalin Capsules

Fineline Cube Jun 20, 2025

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that it has...

Company Drug

Wantai Biological Launches Phase III Trial for VZV-7D Varicella Vaccine

Fineline Cube Jun 20, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation of...

Company Drug

MSD Initiates IDeate-Prostate01 Phase III Trial of Ifinatamab Deruxtecan for mCRPC

Fineline Cube Jun 20, 2025

Merck, Sharp & Dohme (MSD, NYSE: MRK) this week announced the first patient dosing in...

Company Drug

Changchun BCHT Gains NMPA Approval for BK-01 Adjuvanted Influenza Vaccine

Fineline Cube Jun 20, 2025

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) announced that it has received clinical trial...

Company Drug Policy / Regulatory

NMPA’s CDE Reports 4,900 Clinical Trial Filings for Innovative Drugs in 2024

Fineline Cube Jun 20, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released its...

Company Deals Drug

Beijing Science Sun Pharma Inks RMB20M Drug Tech Transfer Pact for NeoAB33 Project

Fineline Cube Jun 20, 2025

Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a Drug Technology Transfer Agreement with...

Posts pagination

1 … 107 108 109 … 633

Recent updates

  • Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer
  • Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers
  • Sandoz Forms Global Biosimilars Unit – Metzger-Led Division Targets Accelerated Portfolio Growth
  • Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion
  • Huadong Medicine’s HDM2017 Wins FDA Orphan Drug Designation – CDH17 ADC Targets Three Gastrointestinal Cancers
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer

Company Drug

Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers

Company

Sandoz Forms Global Biosimilars Unit – Metzger-Led Division Targets Accelerated Portfolio Growth

Company Deals

Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.